Changing patterns of mortality across Europe in patients infected with HIV-1

@article{Mocroft1998ChangingPO,
  title={Changing patterns of mortality across Europe in patients infected with HIV-1},
  author={Amanda Mocroft and Stefano Vella and T Benfield and Antonio M. Chiesi and Veronica Miller and Panagiotis Gargalianos and A d'Arminio Monforte and Israel Yust and J. N. Bruun and Andrew N Phillips and J D Lundgren},
  journal={The Lancet},
  year={1998},
  volume={352},
  pages={1725-1730}
}
View on Elsevier
doi.org
1,315 Citations
Highly Influential Citations
26
Background Citations
227
Methods Citations
12
Results Citations
14

1,315 Citations

Citation Type

Citation Type

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study
TLDR
The proportion of pre-AIDS deaths increased from 1994 to 2001; however, the incidence of pre -AIDS deaths and deaths overall declined; therefore, it is essential to continue to monitor all causes of mortality to identify changes.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
TLDR
In industrialized countries, the mortality experience of HIV-infected patients who start ART and survive the first 6 months continues to be higher than in the general population, but for many patients excess mortality is moderate and comparable with patients having other chronic conditions.
Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals
TLDR
The risk of TCF is declining in Denmark and the prevalence remains stable, and predictors ofTCF were a CD4 cell count below 200, a previous AIDS-defining event, previous antiretroviral exposure, earlier year of HAART initiation, and young age.
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population.
Death rates in the APROCO cohort of 1,157 HIV-1 infected adults starting for the first time a protease inhibitor-containing therapy were standardized to the 1996 French general population mortality…
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
TLDR
Higher mortality rate in North American, compared with European, cohorts was not fully explained by completeness of ascertainment and may be because of the inclusion of more socially marginalized patients with higher mortality risk.
Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania
TLDR
A prognostic model based on hemoglobin level appears to be a useful tool for initial risk assessment in resource-limited settings, with the majority of deaths occurring within 3 months of starting ART.
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries.
TLDR
Early patient losses were increasingly common when programmes were scaled up and were associated with a fee for service and advanced immunodeficiency at baseline, and measures to maximize ART programme retention are required in resource-poor countries.
Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011
TLDR
Despite of significant improvement of survival, there was still a high risk of early death in patients presenting in HAART era, mainly due to late human immunodeficiency virus (HIV) diagnosis and late presentation to care.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Changes in use of antiretroviral therapy in regions of Europe over time
TLDR
Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years, and regional differences in use of antifiltration therapy have decreased, and by September 1997 only minor differences remained.
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
TLDR
The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality in Switzerland.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
TLDR
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Decline in deaths from AIDS due to new antiretrovirals
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
TLDR
The HIV-infected individuals who receivedInitial therapy with regimens including stavudine or lamivudine had significantly lower mortality and longer AIDS-free survival than those who received initial therapy withregimens limited to zidovudine, didanosine, and zalcitabine.
Premature mortality related to AIDS among men and women in Catalonia.
TLDR
According to the current available data, AIDS might become the leading cause of death for the population aged 20-39 years in the near future.
Survival differences in European patients with AIDS, 1979–89
TLDR
Improved survival in recent years was observed for patients with a variety of manifestations used to define AIDS but was significant only for patients diagnosed with Pneumocystis carinii pneumonia, and survival seems to vary within Europe, being shorter in southern than central and northern Europe.
HIV therapy guidelines.
TLDR
Differences lie within the intepretation of this evidence and the expectation of long term benefit from current treatment regimens with the United States groups favouring earlier intervention and a heavier emphasis on the importance of plasma HIV RNA levels.
Impact of AIDS on mortality in San Francisco, 1979-1986.
TLDR
In 1986, AIDS-related diseases were the third leading cause of deaths and the lead cause of YPLL among male San Francisco residents, and occurred in men aged 20-49 years.
British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
...
...